title: Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In reply to Rao et al.
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: J Martin
authors.initials: JM
authors.lastname: Brown
authors.affiliation: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.
authors.forename: David J
authors.initials: DJ
authors.lastname: Carlson
authors.affiliation: Center for Radiological Research, Columbia University Medical Center, New York, New York.
authors.forename: David J
authors.initials: DJ
authors.lastname: Brenner
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000601:surgery*; D016634:Radiosurgery / Q000379:methods*